Podcasts about biotech

Welcome to this episode of Hot Topics on the Edge of Show! Join hosts January Jones and Josh Krieger as they dive into the latest developments in the cryptocurrency world with special guest Josh Lawler from Zuber Lawler.In this episode, we discuss:The recent crypto market crash triggered by President Trump's announcement of a 100% tariff on Chinese imports, leading to significant liquidations and market volatility.The proactive response from Binance, one of the world's largest exchanges, as they offer compensation to affected users.The current status of U.S. crypto legislation amidst the ongoing government shutdown and the implications for the future of the industry.A major $14.2 billion seizure of Bitcoin linked to a vast network of human trafficking and crypto scams, and the questions surrounding victim reparations.Insights into the upcoming Future of Money, Governance, and the Law Summit on October 29th and 30th in Washington, D.C., featuring key players from the crypto industry and government.Don't miss this engaging discussion filled with expert insights and analysis on the evolving landscape of cryptocurrency and regulation.Subscribe to our channel for more episodes and follow us on social media to stay updated on the latest trends in Web3 technology, culture, and innovation!Event Website: https://gbaglobal.org/fomgl/ for summit tickets and more information.Support us through our Sponsors! ☕

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech -- part three in a four part series recorded in-person at Catalyst Pharmaceuticals' Miami headquarters -- Anthony Japour, M.D., CEO at iTolerance, talks about his work as a physician treating infectious diseases, his CEO role in diagnostics at the height of the COVID-19 pandemic, what he learned working as a medical director at a large CRO, and iTolerance's work toward a cure for Type 1 diabetes that doesn't require chronic immunosuppression. Anthony also provides insights on overcoming CMC challenges and how to bypass avoidable detours, the funding climate for preclinical biotechs, and operating in South Florida. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Live from Korea Blockchain Week 2025, join us at The Edge of Show where we dive deep into the evolving world of NFTs, blockchain, and the intersection of sports and technology! This episode features insightful discussions with industry leaders, Jonathan Covey, CMO of Zetachain, Cameron Kates, CEO of Apecoin and NBA superstar Tristan Thompson.In this episode, we explore:The current state and future of the NFT industry, including the new cycles of growth.The dissolution of ApeCoin DAO and the transition to a more agile governance structure.Tristan Thompson's journey into the Web3 space, his new project basketball.fun, and how it empowers fans to engage with their favorite players.The importance of community in decentralized projects and the innovative solutions being developed in the health sector with AxonDAO.Whether you're a crypto enthusiast, a sports fan, or just curious about the future of digital assets, this episode is packed with valuable insights and exciting developments. Don't miss out!Support us through our Sponsors! ☕

Is the future of biotech innovation at risk because of workforce shortages? In this episode, host Elaine Hamm, PhD, talks with Van Ton-Quinlivan, MBA, CEO of Futuro Health and host of the WorkforceRx podcast, about how the biotech and healthcare industries can overcome the growing workforce crisis. Together, they explore how intentional workforce development, stackable credentials, and stronger partnerships between industry and education can help close the talent gap and create a more diverse, sustainable pipeline of healthcare professionals. In this episode, you'll discover: Why workforce shortages—not funding—may be the biggest threat to healthcare innovation. How stackable credentials and education partnerships can expand access to biotech and allied health careers. Strategies for building a diverse and future-ready workforce that keeps innovation moving forward. Tune in to hear how biotech and healthcare leaders can tackle the talent crisis head-on and build a stronger, more resilient future for innovation. Links: Connect with Van Ton-Quinlivan, MBA, and check out Futuro Health and the WorkforceRx podcast. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Check out the California Health Workforce Education and Training Council, Genentech, Kaiser Permanente, and NextFlex. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Biotech's fourth quarter began with a familiar feeling, with indicators pointing toward an improving public market even as political and regulatory uncertainty has buysiders reluctant to say industry has returned to sustainable growth. On the latest BioCentury This Week podcast, BioCentury's analysts assess the state of biotech's public markets. The analysts discuss the Senate's move to limit access to Chinese CDMOs, the latest developments in the White House's “most favored nation” drug pricing negotiations, and the U.K.'s attempt to win over pharma companies via adjusting thresholds at NICE. Finally, they analyze a pair of billion-dollar-plus M&A deals: the $4.7 billion deal by Novo Nordisk to acquire liver disease company Akero and the $1.5 billion takeout of in vivo cell therapy company Orbital by Bristol Myers. This episode of BioCentury This Week is sponsored by Evotec.View full story: https://www.biocentury.com/article/657260#biotech #biopharma #pharma #lifescience #drugpricing #MFN00:01  Sponsor Message: Evotec02:12  4Q Markets Preview13:25  China CDMOs24:35  Drug Pricing Deals NHS31:22  Drug Pricing Deals M&ATo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

We love to hear from our listeners. Send us a message. In this week's episode of the Business of Biotech -- part two in a four-part series recorded in-person at Catalyst Pharmaceuticals' Miami headquarters -- we're speaking with Daniel Teper, an entrepreneur and most recently, founder and CEO at NAYA Therapeutics. Based in South Florida, NAYA is developing NK-engaging bifunctional antibodies and Astatine-211 radiopharmaceuticals targeting hepatocellular carcinoma. Daniel discusses the company's decentralized manufacturing strategy, the current funding climate for early-stage companies, his plan to conduct clinical trials in China, and what's unique about the South Florida life sciences ecosystem.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

The I Love CVille Show headlines: Old Ivy Bridge Reopens, CVille Traffic Back To Normal AstraZeneca, Eli Lilly & Biotech Will Be Historical In Econ Dev Will Biotech Surpass Tourism & Area Econ Dev? Jefferson Council Call Out Double Standards In Prez Search Vinny's Pizza, Miranda's Grill Behind On Rent In Greene Co CVille Featured In Best Fall Foliage Destinations Huge Week For ACC & UVA Football If You Need CVille Office Space, Contact Jerry Miller Read Viewer & Listener Comments Live On-Air The I Love CVille Show airs live Monday – Friday from 12:30 pm – 1:30 pm on The I Love CVille Network. Watch and listen to The I Love CVille Show on Facebook, Instagram, Twitter, LinkedIn, iTunes, Apple Podcast, YouTube, Spotify, Fountain, Amazon Music, Audible, Rumble and iLoveCVille.com.

Send us a textIn this episode of the Life Science Success Podcast my guest is Byron Purse, co-founder of AlidaBio and professor of chemistry at San Diego State University who is pioneering innovative approaches to studying RNA modifications. Byron brings a wealth of expertise in synthetic and natural nucleic acid modifications, with a passion for advancing biotechnology and human health through his groundbreaking research and entrepreneurial endeavors.00:00 Introduction to Life Science Success Podcast00:29 Meet Byron Purse: Professor and Co-Founder of AlidaBio01:05 Byron's Journey into Life Sciences03:10 From Academia to Entrepreneurship06:49 Founding AlidaBio: Vision and Mission08:59 Innovations in RNA Modifications23:09 Challenges and Successes in Developing the EpiPlex™ Platform28:44 Leadership and Inspiration35:00 Concerns and Future Outlook in Life Sciences43:02 Conclusion and Final Thoughts

In this episode, recorded on October 9th, we discuss:Google's Gemini Enterprise: A groundbreaking AI platform that is set to revolutionize workplace automation across various departments like marketing, sales, HR, and finance.California's Pioneering AI Law: Governor Gavin Newsom's new legislation aimed at regulating powerful AI models to prevent misuse and ensure transparency.AI in Governance: Insights from Isabel's Substack, Utopia and Beta, exploring the implications of AI in government, including Albania's appointment of an AI minister.AI in Relationships: A deep dive into how AI companions are impacting human connections and the psychological effects of interacting with AI.Event Alert: Join us for the upcoming Future of Money, Governance, and the Law summit in Washington, D.C. on October 29th and 30th! Learn more at gbaglobal.org.Don't miss out on this engaging conversation about the future of AI and its role in our daily lives!Stay curious, keep pushing boundaries, and subscribe to our channel for more insightful discussions!Support us through our Sponsors! ☕

How to trade and invest in the biotech space with ROTY Biotech Community's Jonathan Faison (0:35). Making money in biotech (5:40). Managing sector risk (9:20). Geron - a stock he never thought he'd own (17:10).Show Notes:Finding Winners In Biotech, Probably The Riskiest SectorSyndax Pharmaceuticals: A Tale Of Two Drug LaunchesArcutis Biotherapeutics: Another Approval Under Their BeltEpisode transcriptsFor full access to analyst ratings, stock and ETF quant scores, and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

Live from Korea Blockchain Week 2025, join us at The Edge of Show as we explore how blockchain and AI are redefining the next frontier of technology and real-world innovation.Host Josh Kriger sits down with Shaw Walters, Founder of Eliza Labs, to unpack the concept of Adaptive Intelligence, a new approach to merging AI and crypto through agent-to-agent economies, generative token networks, and autonomous systems that learn from user behavior. Then Robin Wingardh, co-founder of Wingbits, shares how his team is decentralizing flight tracking data, partnering with major airlines, and building a blockchain network that rewards contributors worldwide.A deep dive into how AI, data, and decentralization are merging to transform industries—from autonomous agents to global aviation.Support us through our Sponsors! ☕

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über ein Oracle-Beben, eine Tesla-Enttäuschung und eine gekürzte Prognose bei BMW. Außerdem geht es um Seagate, Western Digital, Coreweave, Arista Networks, Vertiv, Dell, Tesla, BMW, Aurubis, Trilogy Metals, Recursion Pharmaceuticals, Absci, Oracle, Pfizer, Biontech, Moderna, AMD, IBM, L&G Pharma Breakthrough UCITS ETF (WKN: A2H9XR), Xtrackers MSCI Genomic Healthcare Innovation (WKN: DBX0R2), Aurubis, IBM, Alnylam, Bristol Myers Squib, Innocare, Incyte und Pharming Group, Lonza, AbbVie, Danaher, Vertex, VanEck Quantum Computing ETF (WKN: A418QM), VanEck Quantum Computing ETF (WKN: A418QM), Rigetti, Quantum Computing, D-Wave, IonQ, WisdomTree Quantum Computing ETF (WKN: A419HV), Alphabet, Honeywell, Microsoft und Deutsche Telekom. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article104636888/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

When Dalila Sabaredzovic's sons were diagnosed with an ultra-rare genetic condition, she faced more questions than answers. But through resilience, advocacy, and the power of collaboration, her family's story has become a beacon of hope in rare disease research. In this deeply moving episode of Sounds of Science, Dalila shares her journey from despair to discovery—and how a global village of scientists came together to pursue a personalized treatment that could change everything.Show NotesTaking a Customized and Collaborative Approach to Therapeutic DevelopmentDrug Discovery Services | Charles RiverASO Screening Services | Charles RiverRare Disease Research for Drug Development | Charles RiverTwo in Eight Billion | Eureka blog

In this episode, I talked to Dr. Alexander Marson, cofounder of Arsenal Biosciences and director of the Gladstone-UCSF Institute of Genomic Immunology. He is one of the pioneers of non-viral T-cell editing and is a serial biotech entrepreneur. We talked about Car T-cell Therapy, using CRISPR to edit T-cells, biotech, and his collaboration with Sean Parker, cofounder of Napster. ---------------------------------------------------------------Thanks to the sponsors:Audible: Use my link for a 30-day free trial: http://audibletrial.com/diamondgoatNewsly: https://newsly.mepromo code to receive a 1-month free premium subscription: EARLYMORNING Libysn: https://libsyn.compromo code: DG Dubby Energy: https://www.dubby.ggpromo code for 10% off: DIAMONDGOATOpus Clips:  https://www.opus.pro/?via=diamondgoat----------------------------------------------------------------------------------Listen on:Podcast website: https://www.spreaker.com/podcast/dg-early-morning-show--5943922Spotify: https://open.spotify.com/show/0EuhA6WyuerHtVAqcFrFeOPodcast YT channel clips: https://www.youtube.com/@dgearlymorningshowTiktok: @dgearlymorningshowApple Podcast: https://podcasts.apple.com/us/podcast/dg-early-morning-show/id1575451533Amazon Music: https://music.amazon.com/podcasts/f050b86c-1dad-4bc3-b12f-6aa5fa62438c  Goodpods: https://goodpods.com/podcasts/dg-early-morning-show-211830RadioPublic: https://radiopublic.com/dg-earlymorning-show-WoML4rBreaker: https://www.breaker.audio/dg-early-morning-showReason: https://reason.fm/podcast/dg-earlymorning-show--------------------------------------Check out my other stuff:Instagram: @itzdiamondgoatTwitter: @lildiamondgoatMain YT channel: youtube.com/diamondgoatTiktok: @lildiamondgoatSoundcloud: @Lil DiamondgoatSpotify: @Lil DiamondgoatMerch store: https://diamondgoat.creator-spring.com

Jim Tananbaum of Foresite Capital joins Nick to discuss From Data Science to Drug Design: How AI Shifts Discovery, Target Validation, and Portfolio Construction. In this episode we cover: Data Science and Investment Approach Investment Practices and Market Conditions China's Role in Biotech and Regulatory Considerations Impact of AI on Biotech and Healthcare Healthcare Adoption of AI and Preventive Measures Payers and Insurance Companies' Role Lessons from Successful Investments Generating Liquidity in a Sluggish Market Future of GLP-1 Agonists Guest Links: Jim's LinkedIn Jim's X Foresite's LinkedIn Foresite's Website The host of The Full Ratchet is Nick Moran of New Stack Ventures, a venture capital firm committed to investing in founders outside of the Bay Area. We're proud to partner with Ramp, the modern finance automation platform. Book a demo and get $150—no strings attached.   Want to keep up to date with The Full Ratchet? Follow us on social. You can learn more about New Stack Ventures by visiting our LinkedIn and Twitter.  

It's time to build your family's future on a foundation of true health and freedom. Join us at Future Foundations—because your future generations deserve the best start to the mission that will outlive us… Check it out here. Use code FREEDOM25 for 25% off!    Whether you're looking for tinctures, topicals or teas or a deeper connection to your INNATE healing capacity, Noble Task Homestead is here to serve you. Join the movement. Visit NobleTaskHomestead.com/noblestan today and enjoy a 10% discount on your order.   San Diego area residents, take advantage of our special New Patient offer exclusively for podcast listeners here. We can't wait to experience miracles with you! Welcome to the Future Generations Podcast: Join host Dr. Stanton Ham as he sits down with Tawny Buettner, a pediatric nurse turned health freedom advocate. This powerful episode delves into her groundbreaking lawsuit against Rady Children's Hospital, exploring the critical issues of medical mandates, religious exemptions, and personal sovereignty. Listeners interested in healthcare, parental rights, medical freedom, and systemic challenges in the healthcare industry will find this episode both enlightening and inspiring. Highlights:   1. "The brain is amazing, and if you give it nutrients and love and you create space for it to heal, there's always going to be hope for improvement." 2. "We want a jury of my peers to hear the evidence and to make a ruling." 3. "Don't lose that hope. The brain is amazing, and if you give it nutrients and love, there's always going to be hope for improvement." 4. "We are literally going up against some of the most powerful people in science, biotech, and the medical industry." 5. "It's time to build your family's future on a foundation of true health and freedom."   Timestamps:   1. [0:04:48] - Intro 2. [0:12:41] - The Journey of Advocating for Her Son's Health 3. [0:25:24] - Insights from a CDC Conference on Vaccination Policies 4. [0:58:04] - The Belief System Behind Vaccination Mandates 5. [1:02:27] - A Message of Hope for Parents with Challenged Children 6. [1:12:25] - The Power of Nutrition and Love in Healing 7. [1:16:36] - Call to Action: Supporting the Lawsuit 8. [1:19:06] - How to Find More Information and Support 9. [1:21:28] - Exposing the Connections at Rady Children's Hospital 10. [1:24:52] - Reflecting on the Ongoing Fight for Health Freedom   Resources:   Remember to Rate, Review, and Subscribe on iTunes and Follow us on Spotify!   Learn more about Dr. Stanton Hom on:   Instagram: https://www.instagram.com/drstantonhom  Website: https://futuregenerationssd.com/    Podcast Website: https://thefuturegen.com Twitter: https://twitter.com/drstantonhom  LinkedIn: https://www.linkedin.com/in/stanhomdc  Stay Connected with the Future Generations Podcast:   Instagram:  https://www.instagram.com/futuregenpodcast  Facebook: https://www.facebook.com/futuregenpodcast/    Links:    https://www.thehivemethod.co/ https://www.instagram.com/thehivemethod.co   About:   Tawny Buettner, RN is a pediatric registered nurse with extensive experience working in high-acuity settings, including Level 4 NICUs and the CTICU. Beyond her medical career, she is the proud wife of a retired Marine and mother to two teenagers. Raised in the mountains of California, Tawny grew up in a family deeply rooted in service…her mother a registered nurse, her stepfather a physician and hospital administrator, and her father a retired firefighter who served through historic California emergencies like the Malibu fires and LA riots.   Drawing from both her professional expertise and personal convictions, Tawny has become a passionate advocate for informed consent, medical autonomy, parental rights, and the protection of the doctor-patient relationship free from coercion. She also stands firmly for the preservation of religious freedom, honoring the belief that our bodies are sacred temples of God's Holy Spirit. Tawny's voice is not only shaped by her frontline experiences as a nurse and mother, but also by her unwavering commitment to faith, freedom, and truth.   The desire to go off grid and have the ability to grow your own food has never been stronger than before. No matter the size of your property, Food Forest Abundance can help you design a regenerative layout that utilizes your resources in the most synergistic and sustainable manner. If you are interested in breaking free from the system, please visit www.foodforestabundance.com and use code “thefuturegen” to receive a discount on their incredible services.   Show your eyes some love with a pair of daylight or sunset (or both!) blue-light blocking glasses from Ra Optics. They have graciously offered Future Generations podcast listeners 10% off any purchase. Use code FGPOD or click here to access this discount, and let us know how your glasses are treating you!   One of the single best companies whose clean products have supported the optimal wellness of our family is Earthley Wellness. Long before there was a 2020, Kate Tetje and her team have stood for TRUTH, HEALTH and FREEDOM in ways that paved the way for so many of us. In collaboration with this incredible team, we are proud to offer you 10% off of your first purchase by shopping here.   Are you concerned about food supply insecurity? Our family has rigorously sourced our foods for over a decade and one of our favorite sources is Farm Match and specifically for San Diego locals, “Real Food Club PMA”. My kids are literally made from their maple breakfast sausage and the amazing carnitas we make from their pasture raised pork. We are thrilled to share 10% off your first order when you shop at this link.   Another important way to bolster food security is by supporting local ranchers. Our favorite local regenerative ranch is Perennial Pastures. They have the best nutrient-dense meats that are 100% grass-fed and pasture-raised. You can get $10 off of your first purchase when you use the code: "FUTUREGENERATIONS" at checkout. Start shopping here.

In September, Inside the ICE House aired ten new episodes, four traditional episodes, the new Biotech series, Markets in focus with Opening Bell Daily's Phil Rosen and Inside the ICE House breakfast on the balcony. Biotech Series Episode 1: Alto Neuroscience CEO Dr. Amit Etkin on the Next Chapter in Mental Health Biotech Series Episode 2: Eli Lilly Chief AI Officer Thomas Fuchs on AI's Power to Transform Pharmaceuticals Biotech Series Episode 3: Nimbus CEO Abbas Kazimi on Leading the Future of Precision Therapeutics Biotech Series Episode 4: Enveda CEO Viswa Colluru on the Mission to Decode Nature's Pharmacy Episode 484: ESPN Chairman Jimmy Pitaro on Streaming, Sports Rights, and the Future of Fandom Markets in Focus: Fed Cuts, Labor Market Risks, and Investor Resilience On the Balcony: Founding, Funding, and Investing in the Future with M13's Carter Reum Episode 485: BBDO Worldwide Chairman Andrew Robertson on Shaping the "Creative Shift" Episode 486: VISA's Mathieu Altwegg on Redefining Shopping in an AI-Driven World Episode 487: LexisNexis Risk Solutions' Bill Madison on Data, Decisions, and Smarter Insurance

We love to hear from our listeners. Send us a message. The Business of Biotech is on location in Miami this week! For the first episode in this four-part series on the biotech scene in South Florida, Raquel Cabo, Founder and President of the Miami Biotech Collective, talks about her experiences as a member of the founding team at Ovid Therapeutics, why South Florida needed an organization to connect regional drug developers, what Miami offers to biotech companies and operators, and what gaps in the South Florida life sciences ecosystem still exist.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In this episode, Dr. Karl Pfleger joins us to discuss the evolving landscape of longevity research and investment. He emphasizes the shift from disease-specific approaches to understanding aging as a multifaceted process that underpins many chronic diseases. Dr. Pfleger outlines his investment strategies in the aging biotech sector, highlighting the importance of addressing various sub-pathologies of aging. He also discusses the concept of longevity escape velocity, the challenges of proving longevity therapies, and the role of aging clocks in research.  Learn more about Dr. Karl Pfleger: https://x.com/karlpfleger?lang=en

Our China Healthcare Analyst Jack Lin discusses how China's biotech surge is reshaping healthcare, investment and innovation worldwide.Read more insights from Morgan Stanley.----- Transcript ----- Jack Lin: Welcome to Thoughts on the Market. I'm Jack Lin, from Morgan Stanley's China Healthcare Team. Today, the boom in China biotech – and how it's not just a headline for China-focused investors, but a story that touches all of us. It is Friday, October 3rd at 2pm in Hong Kong. Many people might not realize this but some of the next generation healthcare innovation is being developed far from Silicon Valley and Wall Street. The medicines you rely on, treatment plans that could shape your family's future, even investment opportunity that can grow your savings. They are all increasingly influenced by China's rapidly evolving biotech sector, which is transitioning from traditional generics manufacturing into the global innovation ecosystem. In fact, China's biotech industry is set to become a major player in the global innovation ecosystem. By 2040, we project China's originated assets could represent about a third of U.S. FDA approvals – up dramatically from just 5 percent today. And the question isn't if China's biotech will matter, but how global patients could benefit; and how consumers and investors worldwide might engage with its impact.What's driving this transformation? Three key components are driving the globalization of China originated drug innovations: cost, accessibility, and innovation quality. Lower cost in China's biotech sector enables more efficient development. Clinical trial quality is improving with regulatory pathways becoming more streamlined, promoting accessibility of China innovation for global markets. Finally, innovation in China's biotech sector is gaining momentum with more regionally developed medicines now eyeing market approval from leading overseas agencies like the U.S. FDA and EMA.This is all to say China is on track to become a key force on the global biotech stage. That said, right now we're also at a crossroads moment as geopolitical tensions between U.S. and China pose potential risks to the flow of innovation. Despite these uncertainties, we see a likely outcome of co-opetition, a blend of competition and collaboration, as global pharma grapples with the dual imperatives of innovation and resilience. Of course, this rapid evolution brings both opportunities and challenges. It's prompting stakeholders around the world to rethink their strategies and collaborations in this shifting landscape of global medical innovation. As the China biotech industry evolves, the choices made by investors, policy makers, and healthcare communities, both within China and globally, will determine the therapies of the future. It is truly a dynamic space, and we'll continue to bring you updates. Thanks for listening to our thoughts on the market. If you enjoy the show, please leave us a review, wherever you listen and share Thoughts on the Market with a friend or colleagues today.

This uninterrupted episode is brought to you in partnership with our friends at Timeline. Meet Timeline Chief Brand Officer Jaimee Holmes, whose resume reads like a wish list of dream gigs, with prior roles at Benefit, Ole Henriksen, Too Faced, Marc Jacobs Beauty and Goop. Today, Jaimee tells us everything there is to know about the Swiss biotech company she's proud to lead into the next era in longevity science. Plus, we spill the tea on beauty rebrand hits and misses, including how to know when it's time for a refresh from the Master of the Rebrand herself.You'll learn about:Now backed by L'Oréal's Bold Ventures, why Timeline is poised to become the next big thing in longevity skincareEverything to know about the Swiss biotech company's breakthrough ingredient, Mitopure – powered by Urolithin A and 56 patents – and how it aims to target cellular aging from the inside and outInsider insights on biotech beauty pricing, marketing truths and where the future of the industry is headedPlus, industry hot takes! The CBO offers her opinion on which brands are tops in her books and what it takes for a brand to master its own longevityPssst! Look out for Timeline's first ever, immersive pop-up “Longevity Lab” in SoHo this monthGet social with us and let us know what you think of the episode! Find us on Instagram, Tiktok,X, Threads. Join our private Facebook group. Or give us a call and leave us a voicemail at 1-844-227-0302. Sign up for our Substack here For any products or links mentioned in this episode, check out our website: https://breakingbeautypodcast.com/episode-recaps/ Related episodes like this:Skincare School in Session! Hollywood Facialist Gina Mari On What You May be Getting Wrong in Your Skincare RoutineFresh Beauty co-founder Lev GlazmanCortisol Face, Fascia Care and How-to Brow Lift At Home With The Facialist's Facialist, Maria Cristina BrunoPROMO CODES: When you support our sponsors, you support the creation of Breaking Beauty Podcast! Timeline:If you're curious about Timeline, we have a very special promo code just for our audience. Visit timeline.com/breaking and use the code BREAKING at checkout to get 20% off your entire order. Shop everything mentioned in this episode here: TIMELINE | Mitopure Softgels TIMELINE | Mito-Biotic Eye CreamTIMELINE | Mito-Biotic Dewy CreamTIMELINE | Mito-Biotic Barrier Cream TIMELINE | Mito-Biotic Gentle CleanserTIMELINE | Mito-Biotic Firming SerumTIMELINE | Mito-Biotic Resurfacing Exfoliator *Disclaimer: Unless otherwise stated, all products reviewed are gratis media samples submitted for editorial consideration.* Hosts: Carlene Higgins and Jill Dunn Theme song, used with permission: Cherry Bomb by Saya
 Produced by Dear Media Studio See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Hot Topics on The Edge of Show, January Jones and once again our new guest co-host Isabel Castro are joined by Nimit Sawhney, co-founder of Voatz, to explore how blockchain is transforming election integrity worldwide.From the U.S. government shutdown's impact on crypto regulation to New York's blockchain election integrity bill and a historic case study in Mexico's 2024 federal elections, this conversation reveals how trust, transparency, and digital innovation are reshaping democracy.Key takeaways:The irony of a government shutdown halting crypto regulation.Blockchain for voter registration, ballot tracking, and election security.How Votaz powered overseas voting in Mexico's historic 2024 elections.Why mobile-first blockchain solutions make voting more accessible.Blockchain as a “source of truth” beyond finance.Support us through our Sponsors! ☕

Friday October 3, 2025 Becky McClain Pfizer and The Battle for Biotech Safety

This episode is a practical playbook for biotech job seekers and career climbers who want to interview with clarity, energy, and impact. Carina breaks down 25 common mistakes that quietly cost candidates offers, from rambling to over‑indexing on technical detail to skipping metrics. You'll learn how to answer the actual question asked, thread a positive through‑line across job changes, balance “I” and “we,” and anchor answers with outcomes and numbers. There's tactical guidance for recruiter screens and onsite loops, including how to read cues to be concise, translate jargon, and prepare questions that reveal culture, expectations, and first‑90‑day success metrics. If you're targeting roles across R&D, Quality, Clinical, or G&A in high‑growth biotechs, this episode will help you tighten your elevator pitch, signal motivation for the role and company, avoid negative framing, and follow up like a pro, so you leave every interviewer thinking you're the obvious next hire.Learn more about the Collaboratory Career Hub community and access our free resources:Join our Skool CommunityTake the Free 7-day Interview Sprint ChallengeCheck out our sister podcast: Building BiotechsSend Carina a connection request on LinkedIn!Stay connected with us:

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Die Ölmonarchien investieren gewaltige Summen in Branchen wie KI und Biotech. Vieles spricht gegen einen Erfolg. Doch zuletzt hat sich so manche ökonomische Gewissheit als falsch erwiesen.

In this episode of The Edge of Show, Benjamin Diggles, Co-Founder of Constellation Network, reveals how blockchain is powering real-world utility—from U.S. government contracts to innovations like Digital Evidence, the Builder Program, the Real Estate Ledger, Packaswap for real-world asset tokenization, and Door, a decentralized infrastructure platform that rewards businesses for foot traffic.Key insights include:Why trust is the foundation of the trillion-dollar transparency economy.How developers can seamlessly put data on-chain.Real-world applications in real estate, supply chains, and decentralized infrastructure.The convergence of AI, blockchain, and micropayments.Don't miss this conversation on the future of blockchain adoption and trust in the digital age.Support us through our Sponsors! ☕

You've seen the headlines about new blood tests and treatments for Alzheimer's, Parkinson's, and ALS, but what's the science behind those breakthroughs? In this episode, HudsonAlpha scientists Ben Henderson, PhD, and Bri Rogers, PhD, break down the role of biomarkers and genetics in early detection and treatments of neurodegenerative diseases. Discover how research being conducted today is creating real hope for tomorrow.To go behind the scenes and learn more about this episode, visit “Beyond the Headlines: How Biomarkers and Genetics are Changing Neurodegenerative Disease Research.” If you prefer to watch your podcasts, head over to our Youtube channel. Thanks for listening! We're now on YouTube- follow us here. To receive episode updates and bonus material, subscribe to our mailing list here.

What if biotech teams could automate the most information-intensive parts of bringing a drug to market? In this episode of Data in Biotech, host Ross Katz speaks with Convoke co-founders Alex Telford and Maged Ahmed about building an AI-native knowledge acquisition and curation system for biopharma. Learn how they're transforming clinical research, regulatory writing, and competitive intelligence using LLMs, semantic search, and scalable data infrastructure. ​​What You'll Learn in This Episode: >> How Convoke unifies public and private biotech data into a single workspace for smarter decision-making >> Why structured outputs and semantic layers are key to high-quality AI-driven insights >> Real-world use cases including clinical trial design, competitive landscape analysis, and regulatory documentation >> How feedback loops and model evaluations drive product reliability and user trust >> The future of AI in biotech: continuous decision-making and multimodal intelligence Meet Our Guests Alex Telford is Co-Founder and CEO of Convoke, an AI-native OS transforming drug development workflows. His background in life sciences consulting drives his mission to unify data and streamline outputs like clinical documents and regulatory submissions. Maged Ahmed is Co-Founder of Convoke and a former AI lead at Applied Intuition. He brings deep data infrastructure expertise to biotech, aiming to reduce friction in regulated environments by automating knowledge generation. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Alex Telford  on LinkedIn Connect with Maged Ahmed on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

What makes the Gulf South one of the most exciting—and overlooked—regions for biotech innovation? In this special episode, Elaine Hamm, PhD (Tulane Medicine), Patrick Reed, RTTP (Auburn University), and Marcus Brown, PhD (LSU Health) come together to explore the origins, growth, and future of BIO on the BAYOU, the preeminent event showcasing biotech across the Gulf South. From its beginnings as a collaboration between Tulane and LSU, to its expansion into a regional destination that attracts universities, startups, investors, and global partners, this conversation dives into why BIO on the BAYOU has become a must-attend for biotech leaders (returning October 28 & 29, 2025). In this episode, you'll learn: How BIO on the BAYOU grew from a local idea to a marquee conference drawing national and international attention. Why the Gulf South's overlooked science, startups, and universities are finding their spotlight through this event. The unique mix of panels, pitches, partnering, and New Orleans-style networking that sets BIO on the BAYOU apart. Whether you're a startup founder, an investor, or simply curious about the future of Gulf South biotech, this episode gives you a front-row seat to the story behind BIO on the BAYOU 2025. Links: Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Connect with Patrick Reed, RTTP, and learn about Auburn University. Connect with Marcus Brown, PhD, MBA, and learn about LSU Health New Orleans. Check out the New Orleans BioInnovation Center (NOBIC) and check out their BioChallenge 2025. Check out The Bullpen and PartneringONE. Connect with Ian McLachlan, BIO from the BAYOU producer. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's mid-stage obesity drug, met-097i, has shown "very encouraging" efficacy, supporting Pfizer's proposed $4.9 billion buyout of the company. The drug's performance is seen as positive by BMO Capital Markets. In other news, drug manufacturers are increasingly utilizing artificial intelligence throughout the drug production process, moving from using AI for specific operations to optimizing the entire production process. Additionally, Crystalys, backed by Novo, has debuted with $205 million to tackle gout with its drug dotinurad. The FDA recently singled out Aurinia Pharmaceuticals in a LinkedIn post about surrogate endpoints for lupus nephritis drugs, criticizing companies for not conducting post-approval studies to demonstrate benefits on hard clinical endpoints. Larimar's Friedreich's ataxia drug has faced concerns about anaphylaxis, causing shares to fall. GSK's CEO Emma Walmsley has stepped down after 9 years, resealing pharma's glass ceiling. Upcoming webinars will focus on topics such as mRNA medicine and biopharma in an age of deregulation.

Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Synopsis: When biotech meets bold partnerships, new models of innovation emerge. In this episode of the Biotech 2050 Podcast, host Rahul Chaturvedi welcomes Paul Biondi, Managing Partner at Flagship Pioneering, and Uli Stilz, Vice President, R&D External Innovation Partners at Novo Nordisk, to explore the power of co-creation. Together, they unpack how Flagship's pioneering medicines model and Novo's Bio Innovation Hub intersect to accelerate breakthroughs in obesity, diabetes, and cardiometabolic diseases. They share lessons on building trust, navigating crises, and structuring alliances that go beyond transactions into enduring innovation ecosystems. From human disease atlases to new frameworks for agile collaboration, this episode offers a rare behind-the-scenes look at how pharma and biotech can partner differently—turning complexity into transformative therapies. Biography: Paul Biondi is a Managing Partner at Flagship Pioneering, leading Flagship's product and partnering capabilities, including Pioneering Medicines, Partnering, and Pipeline and Product Innovation. In this role, Paul oversees Pioneering Medicines, Flagship's in-house drug discovery and development unit, as well as therapeutic partnering and business development efforts for the Flagship ecosystem, including driving broad institution-wide Innovation Supply Chain partnerships with biopharma companies to jointly conceive and create innovative products. Paul also works with Flagship company CEOs and their teams to achieve the best attainable value for each company, guiding them in their pipeline strategy, product concepts, R&D execution, and partnering approach. He serves on the boards of Flagship-founded companies, including Tessera Technologies (NASDAQ: TSRA) and Valo Health. Paul Biondi is Managing Partner at Flagship Pioneering, joining after 17 years at Bristol-Myers Squibb (BMS), where he served as SVP of Strategy & Business Development and held leadership roles in R&D. He previously spent nine years at Mercer Management Consulting. Paul earned his MBA from the Kellogg School of Management at Northwestern University and his B.A. from Dartmouth College. Uli Stilz is Corporate Vice President, R&D External Innovation Partners, External & Exploratory Innovation (E2I) at Novo Nordisk., based in Boston. He leads a global R&D team that builds creative partnerships with biotech, venture capital, academia, and research hospitals to co-create next-generation therapeutics in cardiometabolic and rare diseases. Building on the success of the Novo Nordisk Bio Innovation Hub, Uli and the E2I team drive an externally anchored portfolio of collaborations that stimulate global innovation ecosystems and advance Novo Nordisk's pipeline. Uli Stilz earned his Master's in Organic Chemistry from ETH Zürich and a Ph.D. in Biochemistry from the Max-Planck-Institute of Biochemistry in Martinsried, followed by postdoctoral research at Caltech. He began his industry career at Hoechst AG and later Sanofi, where he became Associate VP of the Innovation Unit in the Diabetes Division. Over two decades, he contributed to more than 60 preclinical and clinical drug candidates in cardiometabolic, immunology, and oncology. From 2012–2014, he served as President of the European Federation for Medicinal Chemistry. In 2014, Uli joined Novo Nordisk in Copenhagen and in 2019 moved to Boston to establish and lead the Bio Innovation Hub, now the External & Exploratory Innovation (E2I) organization. He also serves as Adjunct Professor at the University of Frankfurt, sits on editorial and scientific advisory boards, and holds board roles at the Kendall Square Association and Gensaic, while advising the aMoon Fund.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Genmab has acquired Merus, a rising star in the field of oncology, for $8 billion. The acquisition includes Merus' bispecific antibody, petosemtamab, which targets EGFR and LGR5 and has shown potential for head-and-neck cancer. In other news, GSK CEO Emma Walmsley is stepping down after nine years, with Chief Commercial Officer Luke Miels set to replace her next year. The FDA's decision to disclose complete response letters in real-time has raised questions about transparency and the agency's role. Additionally, Biogen has shuffled staff after ending work on AAV, while Heidelberg has cut 75% of its staff after missed royalty payments.The FDA's real-time disclosure of complete response letters benefits investors by providing greater visibility into regulatory decisions. In September, the FDA's actions included boosting Keytruda while rejecting two spinal muscular atrophy therapies due to manufacturing issues. A judge's ruling on the FDA's authority over laboratory-developed tests reflects the impact of a recent Supreme Court decision. Six FDA decisions to watch for in Q4 could have significant implications for the biopharma industry and patients. Recent developments include positive results for an immuneering asset in pancreatic cancer, FDA approval for Lilly's oral SERD for breast cancer, and positive outcomes for uniQure's Huntington's therapy. Additionally, the FDA is streamlining development of cell, gene, and regenerative therapies. Other news includes the revival of a dormant drug as a potential autism treatment, setbacks in obesity studies, and unexpected rejections for certain therapies. Upcoming webinars and job opportunities are also highlighted.Listeners are encouraged to provide feedback on topics they would like to see covered in future episodes.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Rob Abbott, CEO of ISPOR, explains how startup and early-stage clinical drug development companies benefit from conducting health economics and outcomes research (HEOR), and not just with patients and commercial payers. HEOR, viewed as a strategic lever as opposed to a compliance exercise, can help answer investor questions about market differentiation, pricing pathways, and real world product validation. Abbott talks about the value of cost-of-illness studies, burden-of-disease analyses, and payer landscape assessments, and how AI, real world evidence, and patient-centered research can improve drug and trial design and accelerate market access.       Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Join January Jones and co-host Isabelle Castro in this exciting episode of Hot Topics on the Edge of Show, with a special guest, Danny Baer from Meanwhile as they dive deep into the latest trends in the cryptocurrency world!In this episode, we discuss:The recent explosion of cryptocurrency exchange-traded funds (ETFs) and the SEC's new approval process could change the game for investors.The rise of Bitcoin treasuries among corporations, featuring Strive Inc.'s significant acquisition and its implications for corporate strategy.The growing number of crypto millionaires, with insights into their behaviors and how they are navigating their newfound wealth.An in-depth look at Bitcoin life insurance with Danny Baer from Meanwhile Bitcoin Life Insurance, exploring innovative ways to leverage Bitcoin wealth.Whether you're a crypto enthusiast or just curious about the evolving landscape of digital assets, this episode is packed with valuable insights and expert opinions. Don't miss out!Subscribe to our channel for more discussions on the latest in crypto, technology, and innovation. Stay curious, keep pushing boundaries, and follow us on social media to never miss an update!Support us through our Sponsors! ☕

Biotech might produce the world's next trillion-dollar company—and Simba Gill and Steve Ledger are betting on it. Join Jess Larsen as he explores how Serina Therapeutics' drug optimization platform could reshape the future of treatment for Parkinson's, cancer, and beyond. Simba, with four decades of biotech leadership, and Steve, with roots in finance and venture, share how science, capital, and mission come together to drive massive impact. This is a behind-the-scenes look at what happens when breakthrough science collides with visionary leadership. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Grow Everything, hosts Karl Schmieder and Erum Azeez sit down with Dr. Alessandra Zonari, co-founder and Chief Scientific Officer at OneSkin. Alessandra shares her personal journey from Brazil to biotech, driven by a mission to transform how we think about aging. She explains the science of cellular senescence, the discovery of the groundbreaking OS-1 peptide, and why skin is more than a beauty surface—it's a window into systemic health and longevity. Listeners will hear candid insights into the challenges of translating biotech discoveries into consumer products, the importance of radical transparency in science communication, and where peptides and personalized skincare fit into the future of the longevity movement. This is a must-listen for anyone passionate about synthetic biology, sustainable innovation, and the science of healthy agingGrow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at www.messaginglab.com/groweverythingChapters:(00:00:00) Welcome to Grow Everything Podcast(00:00:18) London's Bio Fab Fair Recap(00:02:34) Biotech's Bottom Line Impact(00:05:49) Pharma's Path to Consumer Products(00:08:00) The Accidental Discovery of Splenda(00:09:26) Meet Dr. Alessandra Zonari(00:10:54) A Scientist's Personal Mission(00:13:15) "Zombie Cells" and Skin Aging(00:16:30) Longevity Science vs. Marketing(00:18:28) The Hunt for the OS-01 Peptide(00:21:39) The Five-Year Path to Market(00:22:49) Science-First Communication(00:28:21) The Challenge of Going to Market(00:31:16) Communicating to Beauty vs. Biotech(00:33:45) The Future: Personalized Peptides(00:36:24) Why Science Storytelling Fails(00:38:42) Advice for Scientist-Founders(00:40:00) Peptide vs. SPF(00:40:42) Busting the Biggest Aging Myth(00:41:11) The Future of Personalized Aging(00:43:33) Why Aging is "Excited"(00:44:15) Actress or Astronaut(00:46:17) Peptides as "Cell Messages"Episode Links:Julie wolf episodeOneSkinTopics Covered: skincare, cellular senescence, peptides, OneSkin, skin health, anti aging  Have a question or comment? Message us here:Text or Call (804) 505-5553

Despite a challenging year, the biotech industry has continued to push boundaries, taking bold risks in pursuit of groundbreaking science. If anything, this year has only strengthened our conviction in the rising stars leading the next wave of innovation. Fierce Biotech’s Fierce 15 class of 2025 is defined by their resilience, diversity in both strategy and leadership, and treatments that hold life-changing potential for underserved patients around the world. In this week’s episode of "The Top Line," Fierce Biotech’s Gabrielle Masson and Fierce Pharma’s Andrea Park discuss what went into picking this year’s winners and some highlights from the special report. To learn more about the topics in this episode: Introducing Fierce Biotech's 2025 Fierce 15 See omnystudio.com/listener for privacy information.

Join us for an insightful episode of The Edge of Show featuring Gerard Dache, Founder and Executive Director of the Government Blockchain Association (GBA). In this episode, we dive deep into the future of digital assets, governance, and the law, especially in the context of the upcoming event at the U.S. Capitol titled "The Future of Money Governs the Law."Key topics include:The evolution of money and the role of blockchain in various sectors, including healthcare.The tension between privacy and policy in the digital age.How GBA is influencing public sector challenges through blockchain technology.The importance of regulatory frameworks and standards for blockchain adoption.Don't miss this opportunity to learn about the intersection of technology and governance, and how you can get involved in shaping the future of blockchain.Event Details:Date: October 30thLocation: U.S. Capitol, Washington D.C.Special Offer: Use code EDGEVIP for 20% off gala tickets!For more information, visit https://gbaglobal.org/fomgl/ and check the show notes for links to the event and more resources.Support us through our Sponsors! ☕

In this episode of ClickFunnels Radio, hosts Chris Cameron and Ben Harris sit down with Justin Abrams, a seasoned strategy consultant with over 12 years of experience helping more than 350 clients - from solopreneurs to global companies - scale their businesses. Justin shares his inspiring journey from a career in biotech to becoming the top 1% Upwork consultant and founder of Aryo Consulting. Justin reveals how he pivoted during the pandemic, teaching himself digital marketing through "YouTube University" and transforming that knowledge into a thriving business. Tune in for practical growth strategies and actionable advice you can use to identify your best marketing channel, manage client relationships, and focus daily on high-leverage tasks instead of vanity metrics. https://aryocg.com/

Send us a textHope and Tivon are a husband and wife team of engineering, research and business professionals. They are American expats who live in Marrakech Morocco. Tivon has a background as a US Navy Technician and energy technology engineer. Hope holds an MBA and has a variety of business management experience in both government and corporate finance, small business management and marketing. They run an online engineering academy for the development of clean energy technology devices. They also make handmade products for EMF protection.They are the authors of “Forbidden Tech: The complete guide to energy, social, and biological technologies that they did not want you to know about” The book is a collection of their life's work and research on fringe topics such as free energy, energy weapons, EMF radiation and protection, surveillance and biotechnology. Hope and Tivon have been giving presentations on the latest developments in the emerging technology industry since 2015.  As Christians they feel it is God's calling on their lives to help communicate to people the technology that is currently being used against Gods creation. Everything they disclose is backed by scientific studies, patents, and facts that can be found in the show notes for each of their presentations at their website: https://www.ftwproject.com/SUPPORT THE SHOWBuy Me A Coffee http://buymeacoffee.com/DangerousinfopodcastSubscribeStar http://bit.ly/42Y0qM8Super Chat Tip https://bit.ly/42W7iZHBuzzsprout https://bit.ly/3m50hFTPaypal http://bit.ly/3Gv3ZjpPatreon http://bit.ly/3G3 SMART is the acronym that was created by technocrats that have setup the "internet of things" that will eventually enslave humanity to their needs. Support the showCONNECT WITH USWebsite https://www.dangerousinfopodcast.com/Discord chatroom: https://discord.gg/gggMwCBDEmail the show dangerousinfopodcast@protonmail.comJoin mailing list http://bit.ly/3Kku5YtSOCIALSInstagram https://www.instagram.com/dangerousinfo/Twitter https://twitter.com/jaymz_jesseGab https://gab.com/JessejaymzTruth Social https://truthsocial.com/@jessejaymzWATCH LIVE YouTube https://www.youtube.com/@DANGEROUSINFOPODCASTRumble https://rumble.com/c/DangerousInfoPodcast Twitch https://www.twitch.tv/dangerousinfopodcastPilled https://pilled.net/profile/144176Facebook https://www.facebook.com/DangerousInfoPodcast/BitChute: https://www.bitchute.com/channel/egnticQyZgxDCloutHub https://clouthub.com/DangerousINFOpodcastDLive https://dlive.tv/DangerousINFOpodcast...

We love to hear from our listeners. Send us a message. On this week's episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for conditions as diverse as sleep apnea, rheumatoid arthritis, and generalized anxiety disorder. Joel walks through his funding strategy for the publicly-traded company, his desire to lead in a new category of medicine, and what comes next. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In this episode of Hot Topics on The Edge of Show, we dive into three major stories shaking up the crypto and Web3 ecosystem:Bullish secures a New York BitLicense: What this regulatory green light means for U.S. institutional adoption and the future of exchange competition.Gemini settles with the SEC over Earn: After years of legal battles, what does this resolution signal for crypto regulation and innovation in the U.S.?Relm launches “Falter Web3” insurance: A first-of-its-kind product designed to protect users and institutions from crypto exchange defaults, bankruptcies, and insolvencies.We also share a heartfelt farewell to longtime co-host Richard Carthon, reflecting on his impact and legacy at The Edge of Show.

While the healthcare sector has lagged behind the broader markets, there are pockets of innovation. Asad Haider, head of the US Healthcare Business Unit in Goldman Sachs Research, and Amit Sinha, head of Life Sciences Investing in Goldman Sachs Asset Management, discuss their outlook for the industry. This episode was recorded on September 8 and 15, 2025. The opinions and views expressed herein are as of the date of publication, subject to change without notice, and may not necessarily reflect the institutional views of Goldman Sachs or its affiliates. The material provided is intended for informational purposes only, and does not constitute investment advice, a recommendation from any Goldman Sachs entity to take any particular action, or an offer or solicitation to purchase or sell any securities or financial products. This material may contain forward-looking statements. Past performance is not indicative of future results. Neither Goldman Sachs nor any of its affiliates make any representations or warranties, express or implied, as to the accuracy or completeness of the statements or information contained herein and disclaim any liability whatsoever for reliance on such information for any purpose. Each name of a third-party organization mentioned is the property of the company to which it relates, is used here strictly for informational and identification purposes only and is not used to imply any ownership or license rights between any such company and Goldman Sachs. A transcript is provided for convenience and may differ from the original video or audio content. Goldman Sachs is not responsible for any errors in the transcript. This material should not be copied, distributed, published, or reproduced in whole or in part or disclosed by any recipient to any other person without the express written consent of Goldman Sachs. Disclosures applicable to research with respect to issuers, if any, mentioned herein are available through your Goldman Sachs representative or at http://www.gs.com/research/hedge.html. Goldman Sachs does not endorse any candidate or any political party. © 2025 Goldman Sachs. All rights reserved. Learn more about your ad choices. Visit megaphone.fm/adchoices

Join us for an insightful episode of The Edge of Show as we dive deep into the world of blockchain technology with Douglas Horn, founder of Ease Protocol. In this episode, we explore the potential of stable coins as the next monetary revolution and their implications for global economies.Douglas shares his expertise on the challenges of blockchain adoption, particularly the user experience issues that have historically plagued the crypto space. We discuss how Ease Protocol is addressing these challenges with enterprise-ready solutions that make blockchain accessible and compliant for businesses and governments.Key topics include:The evolution of stable coins and their role in redefining payments and settlements.The importance of user experience in driving crypto adoption compared to AI.How Ease Protocol is building tools for both consumers and enterprises to facilitate seamless blockchain integration.The potential for real-world asset platforms and government applications of blockchain technology.Stay tuned as we also touch on the future roadmap for Ease Protocol, including upcoming features and partnerships that aim to revolutionize the way we think about digital transactions and governance.Don't forget to like, subscribe, and hit the notification bell for more episodes on blockchain innovation and Web3 technology!Support us through our Sponsors! ☕